2018 was a good year for corporate America as earnings were up. The five fastest-growing companies on the 2018 list of the Top 100 Private Companies in NH are prime examples of the diverse industries driving NH’s economy. Below is a profile of one of the fastest-growing private companies in NH.
Jake Reder, CEO, and Joana Murad, director. Photo by Christine Carignan.
Three-Year Avg. Annual Growth: 105%
Rank on Private 100: 74
Headquarters: 16 Cavendish Court, Suite 240, Lebanon 03766
Product/Service: Partners with and provides developmental, financial and business acumen to inventors and institutions to bridge the gaps between discovery and clinical impact of medicines.
CEO: Jake Reder
Total Number of Employees: 22
After five consecutive years on the 10 to Watch list, Celdara Medical’s meteoric rise has not only landed it on this year’s list of the Top 100 Private Companies in NH, but has also made it the fastest-growing company on the list.
Celdara, which has four sites and two affiliates in Seattle and Indianapolis, partners with colleges and universities to transform promising research into marketable medical therapies.
The company has developed two cancer therapies that are in clinical trials and several more in preclinical trials, says CEO Jake Reder, adding that there’s a robust pipeline beyond that.
“In terms of activity, we are at an all-time high,” Reder says.
Celdara also provides a diagnostic service to help pharmaceutical firms determine which patients should be in clinical trials, a growing source of revenue for the firm. And the company made its first investment in a startup, Javelin Oncology, which is domiciled in Celdara’s lab in Lebanon. Reder says Javelin uses a different approach to cancer treatment. He says patients are usually treated for cancer based on the organ under attack. Javelin identifies specific cell targets and treats those. “It’s a new way of thinking about cancer treatment,” Reder says, noting that other scientists are also
While Celdara landed on this list due to its fast growth in revenue (105 percent average annual growth between 2015 and 2017), Reder measures success differently. “When I think of a legacy of a company, I think of it in terms of lives saved,” he says, pointing out that patients in Celdara trials are responding to treatments. “It’s the ability to change what it means to be diagnosed with a disease.”